Ubrigene key facts
as of Oct 2026- Provider of gene and cell therapy contract research services intended to assist drug development companies.
- Ubrigene is valued at approximately $50.8M as of Oct 2026 (last reported valuation).
- It has raised $142.9M; the latest was Later Stage VC ($27.5M) in Dec 2024.
- Notable investors include Addor Capital, Cowin Capital, IDG Capital, Guotai Junan Innovation Investment, Chiron Ventures — 18 tracked in total.
- Status: Privately Held (backing).
Ubrigene's last reported valuation, Dec 2020. Nothing priced has surfaced since.
- ·The complete investor list: 18 names
- ·Watch Ubrigene: the Monday email on marks, rounds and moves
Ubrigene funding rounds
No funding rounds for Ubrigene are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Ubrigene
18+Ubrigene valuation
Ubrigene's last reported valuation was $50.8 million in Dec 2020. No priced round, secondary trade or fund mark has surfaced since.
Ubrigene investors
18 investors are on record for Ubrigene, including Addor Capital, Cowin Capital, IDG Capital and Guotai Junan Innovation Investment.
About Ubrigene
Provider of gene and cell therapy contract research services intended to assist drug development companies. The company's research focuses on GMP, CAR-T Plasmid, and various viral vectors, enabling pharmaceutical enterprises to outsource research and improve drug discovery efficiency.
- Sector
- Healthcare
- HQ
- Suzhou, China
- Founded
- 2015
- Employees
- 300
- Website
- ubrigene.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.